Welcome to our dedicated page for Biotage Unsponso news (Ticker: BITGY), a resource for investors and traders seeking the latest updates and insights on Biotage Unsponso stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biotage Unsponso's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biotage Unsponso's position in the market.
Biotage AB has scheduled its Annual General Meeting for April 28, 2021, to be conducted via advance voting due to Covid-19 precautions. Shareholders must register by April 20, 2021, and submit their advance votes by April 27, 2021. Key agenda items include the election of board members, approval of the annual report, and a proposed dividend of SEK 1.50 per share. A long-term incentive plan is also proposed, allowing up to 18 employees to earn performance-based shares. The total number of shares eligible for voting at the meeting is 65,201,784.
Biotage AB has released its 2020 Annual Report, Corporate Governance Report, and Remuneration Report. The reports are now available for download at www.biotage.com. The company reported sales of 1,092 MSEK in 2020 and operates globally, serving various sectors including pharmaceuticals, biotech, and environmental testing. Biotage aims to contribute to sustainable science and is listed in the Mid Cap segment on NASDAQ Stockholm under the symbol BITGY.
Biotage reported a successful fourth quarter of 2020 with net sales of 298.1 MSEK, a 3.3% increase year-over-year, and a significant 10% organic growth. The operating profit reached 59.6 MSEK with a margin of 20%. For the full year, net sales totaled 1,092.3 MSEK, a slight 0.8% decrease compared to 2019, yet organic growth stood at 1.4%. The cash flow from operations increased to 279.0 MSEK, and the company boasts a strong net cash position of 157.0 MSEK. A dividend of 1.50 SEK per share is proposed for shareholders, reflecting a commitment to returning value.